Home About Us Pipeline News Investors Contacts Careers

Covid-19 Pandemic

Treatment with NERLYNX® during the COVID-19 Pandemic

At Puma Biotechnology, the long term health of our patients is our priority and therefore we recommend that all patients follow federal and state guidelines during the pandemic. In response to questions from patients, Puma wants to confirm that the available clinical and non-clinical data do not demonstrate any negative effect of NERLYNX® (neratinib) on the immune system. Treatment with NERLYNX does not place patients at greater risk of acquiring or responding to the COVID-19 virus. Patients starting or continuing treatment should follow the advice of their treating physician.

Puma maintains significant stock of NERLYNX and does not anticipate any disruption of supply to existing or new patients.

Support Services

Health Care Professionals with any questions should call at 1-844-NERLYNX (1-844-637-5969). Patients with any questions should call Puma’s Medical Inquiry line at 1-844-MED-PUMA (1-844-633-7862). Our centers are dedicated to providing additional resources to patients and caregivers, 24 hours per day, 7 days per week.

Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax